Cost-effectiveness of proton beam therapy for intraocular melanoma

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Moriarty, James P ^a   Borah, Bijan J ^a   Foote, Robert L ^a   Pulido, Jose S ^a   Shah, Nilay D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRACHYTHERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ENUCLEATION; HEALTH CARE COST; HIDDEN MARKOV MODEL; HUMAN; INTRAOCULAR TUMOR; MAJOR CLINICAL STUDY; MELANOMA; PROTON THERAPY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; UNCERTAINTY; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMIC MODEL; ECONOMICS; EYE ENUCLEATION; MARKOV CHAIN; MIDDLE AGED; TREATMENT OUTCOME; UVEAL NEOPLASMS;

BRACHYTHERAPY; COST-BENEFIT ANALYSIS; EYE ENUCLEATION; HUMANS; MARKOV CHAINS; MELANOMA; MIDDLE AGED; MODELS, ECONOMIC; PROTON THERAPY; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME; UVEAL NEOPLASMS;

EID: 84930655477     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127814     Document Type: Article

References (62)

1. Sugerman DT. JAMA patient page. Robotic surgery. Jama. 2013; 310(10):1086. http://dx.doi.org/10.1001/jama.2013.75621. PMID: 24026615. doi: 10.1001/jama.2013.75621
2. Weissman JS, Zinner M. Comparative effectiveness research on robotic surgery. Jama. 2013; 309(7):721-2. http://dx.doi.org/10.1001/jama.2013.1107. PMID: 23423419. doi: 10.1001/jama.2013.1107
3. Goitein M, Jermann M. The relative costs of proton and X-ray radiation therapy. Clin Oncol (R Coll Radiol). 2003; 15(1):S37-50. PMID: 12602563.
4. Goozner M. The proton beam debate: are facilities outstripping the evidence? J Natl Cancer Inst. 2010; 102(7):450-3. http://dx.doi.org/10.1093/jnci/djq112. PMID: 20339139. doi: 10.1093/jnci/djq112
5. Gray PJ, Efstathiou JA. Proton beam radiation therapy for prostate cancer-is the hype (and the cost) justified? Curr Urol Rep. 2013; 14(3):199-208. Epub 2013/04/03. doi: 10.1007/s11934-013-0320-2 PMID: 23546839.
6. Grutters JPC, Abrams KR, de Ruysscher D, Pijls-Johannesma M, Peters HJM, Beutner E, et al. When to wait for more evidence? Real options analysis in proton therapy. Oncologist. 2011; 16(12):1752-61. http://dx.doi.org/10.1634/theoncologist.2011-0029. PMID: 22147003; PubMed Central PMCID: PMCPMC3248774 [Available on 12/01/12]. doi: 10.1634/theoncologist.2011-0029
7. Jarosek S, Elliott S, Virnig BA. Proton beam radiotherapy in the U.S. Medicare population: growth in use between 2006 and 2009: Data Points # 10. Data Points Publication Series. Rockville MD2011.
8. Konski A, Speier W, Hanlon A, Beck JR, Pollack A. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol. 2007; 25(24):3603-8. PMID: 17704408.
9. Lawrence TS, Feng M. Protons for prostate cancer: the dream versus the reality. J Natl Cancer Inst. 2013; 105(1):7-8. http://dx.doi.org/10.1093/jnci/djs509. PMID: 23243201. doi: 10.1093/jnci/djs509
10. Lievens Y, Pijls-Johannesma M. Health economic controversy and cost-effectiveness of proton therapy. Semin Radiat Oncol. 2013; 23(2):134-41. Epub 2013/03/12. doi: 10.1016/j.semradonc.2012.11.005 PMID: 23473691.
11. Lodge M, Pijls-Johannesma M, Stirk L, Munro AJ, De Ruysscher D, Jefferson T. A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancer. Radiother Oncol. 2007; 83(2):110-22. PMID: 17502116.
12. Lundkvist J, Ekman M, Ericsson SR, Isacsson U, Jonsson B, Glimelius B. Economic evaluation of proton radiation therapy in the treatment of breast cancer. Radiother Oncol. 2005; 75(2):179-85. PMID: 15885828.
13. Peeters A, Grutters JPC, Pijls-Johannesma M, Reimoser S, De Ruysscher D, Severens JL, et al. How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiother Oncol. 2010; 95(1):45-53. http://dx.doi.org/10.1016/j.radonc.2009.12.002. PMID: 20106540. doi: 10.1016/j.radonc.2009.12.002
14. Pijls-Johannesma M, Pommier P, Lievens Y. Cost-effectiveness of particle therapy: current evidence and future needs. Radiother Oncol. 2008; 89(2):127-34. http://dx.doi.org/10.1016/j.radonc.2008.07.015. PMID: 18707784. doi: 10.1016/j.radonc.2008.07.015
15. Terasawa T, Dvorak T, Ip S, Raman G, Lau J, Trikalinos TA. Systematic review: charged-particle radiation therapy for cancer. Ann Intern Med. 2009; 151(8):556-65. PMID: 19755348.
16. Yu JB, Soulos PR, Herrin J, Cramer LD, Potosky AL, Roberts KB, et al. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst. 2013; 105(1):25-32. http://dx.doi.org/10.1093/jnci/djs463. PMID: 23243199; PubMed Central PMCID: PMCPMC3536640. doi: 10.1093/jnci/djs463
17. Engelberg AB, Kesselheim AS, Avorn J. Balancing innovation, access, and profits - market exclusivity for biologics.[Erratum appears in N Engl J Med. 2010 Dec 9;363(24):2374], [Erratum appears in N Engl J Med. 2010 Feb 18;362(7):664]. N Engl J Med. 2009; 361(20):1917-9. http://dx.doi.org/10.1056/NEJMp0908496. PMID: 19828525. doi: 10.1056/NEJMp0908496
18. Wheadon DE. Market exclusivity for biologics. N Engl J Med. 2010; 362(7):661; author reply -2. http://dx.doi.org/10.1056/NEJMc0912463. PMID: 20164494. doi: 10.1056/NEJMc0912463
19. Chandra A. TEDxCambridge - Amitabh Chandra on fixing American healthcare [October 11, 2013]. Available from: http://tedxtalks.ted.com/video/TEDxCambridge-Amitabh-Chandra-o.
20. Emanuel EJ, Pearson SD. It Costs More, but is it Worth More? The New York Times. 2012 January 2, 2012.
21. Langreth R. Prostate Cancer Therapy Too Good to Be True Explodes Health Cost. Bloomberg Businessweek. 2012 March 25, 2012.
22. Wang Z, Nabhan M, Schild SE, Stafford SL, Petersen IA, Foote RL, et al. Charged particle radiation therapy for uveal melanoma: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2013; 86(1):18-26. http://dx.doi.org/10.1016/j.ijrobp.2012.08.026. PMID: 23040219. doi: 10.1016/j.ijrobp.2012.08.026
23. Hawkins BS. Collaborative ocular melanoma study randomized trial of I-125 brachytherapy. Clin. 2011; 8(5):661-73. http://dx.doi.org/10.1177/1740774511419684. PMID: 22013172.
24. Damato B, Kacperek A, Chopra M, Campbell IR, Errington RD. Proton beam radiotherapy of choroidal melanoma: the Liverpool-Clatterbridge experience. Int J Radiat Oncol Biol Phys. 2005; 62(5):1405-11. Epub 2005/07/21. doi: 10.1016/j.ijrobp.2005.01.016 PMID: 16029800.
25. Dendale R, Lumbroso-Le Rouic L, Noel G, Feuvret L, Levy C, Delacroix S, et al. Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO). Int J Radiat Oncol Biol Phys. 2006; 65(3):780-7. Epub 2006/05/02. doi: 10.1016/j.ijrobp.2006.01.020 PMID: 16647221.
26. Munzenrider JE. Uveal melanomas. Conservation treatment. Hematol Oncol Clin North Am. 2001; 15(2):389-402. PMID: 11370500.
27. Char DH, Quivey JM, Castro JR, Kroll S, Phillips T. Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial. Ophthalmology. 1993; 100(10):1547-54. PMID: 8414414.
28. Damato B, Lecuona K. Conservation of eyes with choroidal melanoma by a multimodality approach to treatment: an audit of 1632 patients. Ophthalmology. 2004; 111(5):977-83. PMID: 15121377.
29. Hawkins BS, Collaborative Ocular Melanoma Study G. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. Am J Ophthalmol. 2004; 138(6):936-51. PMID: 15629284.
30. Li W, Gragoudas ES, Egan KM. Metastatic melanoma death rates by anatomic site after proton beam irradiation for uveal melanoma. Arch Ophthalmol. 2000; 118(8):1066-70. Epub 2000/08/02. PMID: 10922199.
31. Shields CL, Furuta M, Thangappan A, Nagori S, Mashayekhi A, Lally DR, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009; 127(8):989-98. http://dx.doi.org/10.1001/archophthalmol.2009.208. PMID: 19667335. doi: 10.1001/archophthalmol.2009.208
32. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005; 123(12):1639-43. PMID: 16344433.
33. Naimark DMJ, Bott M, Krahn M. The half-cycle correction explained: two alternative pedagogical approaches. Medical Decision Making. 2008; 28(5):706-12. PMID: 18448700. doi: 10.1177/0272989X08315241
34. Jampol LM, Moy CS, Murray TG, Reynolds SM, Albert DM, Schachat AP, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19.[Erratum appears in Ophthalmology. 2004 Aug;111(8):1514]. Ophthalmology. 2002; 109(12):2197-206. PMID: 12466159.
35. Arias E. United States Life Tables, 2008. National Center for Health Statistics; 2012.
36. Riley GF. Administrative and claims records as sources of health care cost data. Med Care. 2009; 47(7 Suppl 1):S51-5. http://dx.doi.org/10.1097/MLR.0b013e31819c95aa. PMID: 19536019. doi: 10.1097/MLR.0b013e31819c95aa
37. HCUP Nationwide Inpatient Sample (NIS) Rockville, MD: Agency for Healthcare Research and Quality; 2010. Available from: www.hcup-us.ahrq.gov/nisoverview.jsp.
38. Cost-to-Charge Ratio Files: 2010 Nationwide Inpatient Sample (NIS) User Guide Rockville, MD: Agency for Healthcare Quality and Research; 2010 [October 11, 2013]. Available from: http://www.hcup-us.ahrq.gov/db/state/CCR2010NISUserGuide.pdf.
39. Chastek B, Harley C, Kallich J, Newcomer L, Paoli CJ, Teitelbaum AH. Health care costs for patients with cancer at the end of life. J Oncol Pract. 2012; 8(6):75s-80s. Epub 2013/04/20. doi: 10.1200/jop.2011.000469 PMID: 23598848; PubMed Central PMCID: PMC3500487.
40. Medical Expenditure Panel Survey: Using appropriate price indices for analyses of health care expenditures or income across multiple years: Agency for Healthcare Research and Quality; 2013 [October 22, 2013]. Available from: http://meps.ahrq.gov/mepsweb/about-meps/Price-Index.shtml.
41. Health Economics Research Center. A3. How do I adjust for the effects of inflation?: U.S. Dapartment of Veterans Affairs; 2013 [updated March 15, 2013October 22, 2013]. Available from: http://www.herc.research.va.gov/resources/faq-a03.asp.
42. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. Jama. 1996; 276(15):1253-8. PMID: 8849754.
43. Torrance GW. Measurement of health state utilities for economic appraisal. Journal of Health Economics. 1986; 5(1):1-30. PMID: 10311607.
44. Crott R, Ali F, Burdette-Radoux S. Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec. Value in Health. 2004; 7(4):423-32. PMID: 15449634.
45. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Medical Decision Making. 2000; 20(3):332-42. PMID: 10929856.
46. Bekkering GE, Rutjes AWS, Vlassov VV, Aebersold DM, von Bremen K, Juni P, et al. The effectiveness and safety of proton radiation therapy for indications of the eye: a systematic review. Strahlenther Onkol. 2009; 185(4):211-21. http://dx.doi.org/10.1007/s00066-009-1900-4. PMID: 19370423. doi: 10.1007/s00066-009-1900-4
47. Bonner L. CMS won't budge on proton therapy cuts: DOTmed Daily News; 2012 [October 22, 2013]. Available from: http://www.dotmed.com/news/.
48. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value in Health. 2003; 6(1):9-17. PMID: 12535234.
49. Sagoo MS, Shields CL, Mashayekhi A, Freire J, Emrich J, Reiff J, et al. Plaque radiotherapy for juxtapapillary choroidal melanoma: tumor control in 650 consecutive cases. Ophthalmology. 2011; 118(2):402-7. http://dx.doi.org/10.1016/j.ophtha.2010.06.007. PMID: 20813410. doi: 10.1016/j.ophtha.2010.06.007
50. Gragoudas ES, Lane AM, Munzenrider J, Egan KM, Li W. Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma. Trans Am Ophthalmol Soc. 2002; 100:43-8; discussion 8-9. Epub 2003/01/28. PMID: 12545676; PubMed Central PMCID: PMC1358945.
51. Caujolle J-P, Paoli V, Chamorey E, Maschi C, Baillif S, Herault J, et al. Local recurrence after uveal melanoma proton beam therapy: recurrence types and prognostic consequences. Int J Radiat Oncol Biol Phys. 2013; 85(5):1218-24. http://dx.doi.org/10.1016/j.ijrobp.2012.10.005. PMID: 23177670. doi: 10.1016/j.ijrobp.2012.10.005
52. Lane AM, Egan KM, Kim IK, Gragoudas ES. Mortality after diagnosis of small melanocytic lesions of the choroid. Arch Ophthalmol. 2010; 128(8):996-1000. http://dx.doi.org/10.1001/archophthalmol.2010.166. PMID: 20696999. doi: 10.1001/archophthalmol.2010.166
53. Puusaari I, Heikkonen J, Summanen P, Tarkkanen A, Kivela T. Iodine brachytherapy as an alternative to enucleation for large uveal melanomas. Ophthalmology. 2003; 110(11):2223-34. PMID: 14597534.
54. Marucci L, Ancukiewicz M, Lane AM, Collier JM, Gragoudas ES, Munzenrider JE. Uveal melanoma recurrence after fractionated proton beam therapy: comparison of survival in patients treated with reirradiation or with enucleation. Int J Radiat Oncol Biol Phys. 2011; 79(3):842-6. http://dx.doi.org/10.1016/j.ijrobp.2009.12.018. PMID: 20472356. doi: 10.1016/j.ijrobp.2009.12.018
55. Gunduz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW. Plaque radiotherapy of uveal melanoma with predominant ciliary body involvement. Arch Ophthalmol. 1999; 117(2):170-7. PMID: 10037560.
56. Jensen AW, Petersen IA, Kline RW, Stafford SL, Schomberg PJ, Robertson DM. Radiation complications and tumor control after 125I plaque brachytherapy for ocular melanoma. Int J Radiat Oncol Biol Phys. 2005; 63(1):101-8. PMID: 16111577.
57. Collaborative Ocular Melanoma Study G. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol. 2006; 124(12):1684-93. PMID: 17159027.
58. Collaborative Ocular Melanoma Study G. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma III: local complications and observations following enucleation COMS report no. 11. Am J Ophthalmol. 1998; 126(3):362-72. PMID: 9744369.
59. Brown GC, Brown MM, Sharma S. Analysis of costs. Arch Ophthalmol. 2000; 118(3):444. PMID: 10721980.
60. Riley GF, Lubitz JD. Long-term trends in Medicare payments in the last year of life. Health Services Research. 2010; 45(2):565-76. PMID: 20148984. doi: 10.1111/j.1475-6773.2010.01082.x
61. Cruickshanks KJ, Fryback DG, Nondahl DM, Robinson N, Keesey U, Dalton DS, et al. Treatment choice and quality of life in patients with choroidal melanoma. Arch Ophthalmol. 1999; 117(4):461-7. PMID: 10206573.
62. Suchocka-Capuano A, Bredart A, Dolbeault S, Rouic LL-L, Levy-Gabriel C, Desjardins L, et al. [Quality of life and psychological state in patients with choroidal melanoma: longitudinal study]. Bulletin du Cancer. 2011; 98(2):97-107. PMID: 21382791. doi: 10.1684/bdc.2011.1300